Boichuk, S.; Dunaev, P.; Mustafin, I.; Mani, S.; Syuzov, K.; Valeeva, E.; Bikinieva, F.; Galembikova, A.
Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells. Biomedicines 2022, 10, 601.
https://doi.org/10.3390/biomedicines10030601
AMA Style
Boichuk S, Dunaev P, Mustafin I, Mani S, Syuzov K, Valeeva E, Bikinieva F, Galembikova A.
Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells. Biomedicines. 2022; 10(3):601.
https://doi.org/10.3390/biomedicines10030601
Chicago/Turabian Style
Boichuk, Sergei, Pavel Dunaev, Ilshat Mustafin, Shinjit Mani, Kirill Syuzov, Elena Valeeva, Firuza Bikinieva, and Aigul Galembikova.
2022. "Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells" Biomedicines 10, no. 3: 601.
https://doi.org/10.3390/biomedicines10030601
APA Style
Boichuk, S., Dunaev, P., Mustafin, I., Mani, S., Syuzov, K., Valeeva, E., Bikinieva, F., & Galembikova, A.
(2022). Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells. Biomedicines, 10(3), 601.
https://doi.org/10.3390/biomedicines10030601